Nicorandil
- Generic Name
- Nicorandil
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C8H9N3O4
- CAS Number
- 65141-46-0
- Unique Ingredient Identifier
- 260456HAM0
- Background
Nicorandil is an orally efficacious vasodilatory drug and antianginal agent marketed in the UK, Australia, most of Europe, India, Philippines, Japan, South Korea, and Taiwan. It is not an approved drug by FDA. It is a niacinamide derivative that induces vasodilation of arterioles and large coronary arteries by activating potassium channels. It is often used ...
- Indication
Indicated for the prevention and treatment of chronic stable angina pectoris and reduction in the risk of acute coronary syndromes.
- Associated Conditions
- Angina Pectoris
- Associated Therapies
- -
Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Either Osimertinib in Participants With Unresectable, Locally Advanced, or Metastatic Non-Small Cell Lung Cancer, or With Cetuximab in Participants With Metastatic Colorectal Cancer
- Conditions
- Interventions
- First Posted Date
- 2023-07-20
- Last Posted Date
- 2024-12-02
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 172
- Registration Number
- NCT05954871
- Locations
- 🇺🇸
Yale Cancer Center, New Haven, Connecticut, United States
🇺🇸Christiana Care Health System, Newark, Delaware, United States
🇺🇸SCRI Oncology Partners, Nashville, Tennessee, United States
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-1971 in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Solid Tumors
- Conditions
- Interventions
- First Posted Date
- 2022-08-04
- Last Posted Date
- 2024-12-20
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 232
- Registration Number
- NCT05487235
- Locations
- 🇺🇸
Virginia Cancer Specialists, Fairfax, Virginia, United States
🇵🇱Uniwersytecki Szpital Kliniczny w Poznaniu, Pozna?, Poland
🇪🇸NEXT Oncology-Hospital Quironsalud Madrid, Pozuelo de Alarcon, Madrid, Spain
A Study to Evaluate the Impact of Pre-procedural Intracoronary Nicorandil Injection to PREVENT ReductioN of DecREased TIMI FLOW in Patients Who Undergoing Percutaneous Coronary Intervention for the Coronary Artery Disease
- Conditions
- Interventions
- First Posted Date
- 2022-06-22
- Last Posted Date
- 2024-10-10
- Lead Sponsor
- Korea University Anam Hospital
- Target Recruit Count
- 460
- Registration Number
- NCT05427786
- Locations
- 🇰🇷
Korea University Anam Hospital, Seoul, Korea, Republic of
Intracoronary of Nicorandil and Verapamil to Reduce the Occurrence of Periprocedural Myocardial Injury
- First Posted Date
- 2022-06-01
- Last Posted Date
- 2022-06-01
- Target Recruit Count
- 150
- Registration Number
- NCT05399576
- Locations
- 🇨🇳
yuangang Qiu, Hangzhou, Zhejiang, China
The Effect of Nicorandil on Left Ventricular Myocardial Strain in Patients With Coronary Chronic Total Occlusion
- First Posted Date
- 2021-10-21
- Last Posted Date
- 2021-10-21
- Lead Sponsor
- Peking University Third Hospital
- Target Recruit Count
- 61
- Registration Number
- NCT05087797
- Locations
- 🇨🇳
Peking University Third Hospital, Beijing, Beijing, China
Effect of Nicorandil on Cardiac Sympathetic Nerve for the Patients of Acute ST Segment Elevation Myocardial Infarction
- First Posted Date
- 2021-04-01
- Last Posted Date
- 2021-04-01
- Lead Sponsor
- Xuzhou Central Hospital
- Target Recruit Count
- 80
- Registration Number
- NCT04826497
Clinical Efficacy and sAfety of Intravenous Infusion of Nicorandil During Primary Percutaneous Coronary Intervention
- Conditions
- Interventions
- First Posted Date
- 2020-12-11
- Last Posted Date
- 2023-09-14
- Lead Sponsor
- Fudan University
- Target Recruit Count
- 1500
- Registration Number
- NCT04665648
- Locations
- 🇨🇳
Zhongshan Hospital, Shanghai, Shanghai, China
A Study to Evaluate the Safety, Pharmacokinetics, and Activity of GDC-6036 Alone or in Combination in Participants With Advanced or Metastatic Solid Tumors With a KRAS G12C Mutation
- First Posted Date
- 2020-06-29
- Last Posted Date
- 2024-12-09
- Lead Sponsor
- Genentech, Inc.
- Target Recruit Count
- 498
- Registration Number
- NCT04449874
- Locations
- 🇺🇸
UPMC - Hillman Cancer Center, Pittsburgh, Pennsylvania, United States
🇺🇸Dana Farber Cancer Institute, Boston, Massachusetts, United States
🇺🇸Univ of Calif, San Francisco; Breast Cancer Center, San Francisco, California, United States
Safety and Modulation of ABCC9 Pathways by Nicorandil for the Treatment of Hippocampal Sclerosis of Aging
- Conditions
- Interventions
- First Posted Date
- 2019-10-09
- Last Posted Date
- 2024-11-27
- Lead Sponsor
- Gregory Jicha, MD, PhD
- Target Recruit Count
- 64
- Registration Number
- NCT04120766
- Locations
- 🇺🇸
University of Kentucky, Lexington, Kentucky, United States
Regulation of KATP Channels and Na+/K+ ATPase in Relation to Fatigue Development
- First Posted Date
- 2018-12-14
- Last Posted Date
- 2023-07-06
- Lead Sponsor
- University of Copenhagen
- Target Recruit Count
- 16
- Registration Number
- NCT03775902
- Locations
- 🇩🇰
University of Copenhagen, Copenhagen, Danmark, Denmark
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.